1. Background {#sec0005}
=============

The *S. nigra* plant belongs to the Adoxaceae family, which is indigenous to Europe, Asia and North Africa \[[@bib0005]\]. Historically, the flower and berry of the Elder plant have been used in herbal preparations for the treatment of common cold and flu \[[@bib0005]\]. Preclinical studies have shown elderberry extracts to have antimicrobial and antiviral effects, including activity against influenza viruses \[[@bib0010]\]. These antiviral effects have been attributed to the inhibition of viral replication by *S.nigra*. Additionally, elderberry extracts have been shown to increase cytokines that activate immunomodulation \[[@bib0015]\].

*S.nigra* berries contain multiple constituents, including flavonoids, triterpenes, acyl spermidines, α-linolenic acid, linoleic acid \[[@bib0005]\], mucilage and hydroxycinnamic acid derivatives \[[@bib0020]\]. The rich anthocycanin flavonoid content is associated with antioxidant activity \[[@bib0025]\]. The unripe berries also contain toxic constituents, but these are lost during drying and heating processes; as such, these toxic constituents are not typically present in commercially available preparations \[[@bib0015]\].

2. Search strategy {#sec0010}
==================

2.1. Research question {#sec0015}
----------------------

Does *S.nigra improve* outcomes in humans with acute respiratory viral infections?

2.2. Inclusion/exclusion criteria {#sec0020}
---------------------------------

### 2.2.1. Inclusion criteria {#sec0025}

Original prospective intervention studies involving adult participants with acute respiratory viral infections written in English that evaluated the effect of *S.nigra* (as a mono- or combination therapy) in any form, dose and route of administration. All comparators or controls were included.

### 2.2.2. Exclusion criteria {#sec0030}

Studies soley involving children, or participants with bacterial, fungal or non-infectious respiratory disease and not meeting the inclusion criteria above were excluded from this review.

2.3. Databases {#sec0035}
--------------

Relevant studies were identified by searching MEDLINE (Ovid), EMBASE (Ovid), AMED (Ovid) and CINAHL (EBSCO) for articles published from inception to May 2020.

2.4. Search terms {#sec0040}
-----------------

Example -- MEDLINE (Ovid):

(((Randomized Controlled Trials as Topic/ OR randomized controlled trial/ OR Random Allocation/ OR Double Blind Method/ OR Single Blind Method/ OR clinical trial/ OR clinical trial, phase i.pt. OR clinical trial, phase ii.pt. OR clinical trial, phase iii.pt. OR clinical trial, phase iv.pt. OR controlled clinical trial.pt. OR randomized controlled trial.pt. OR multicenter study.pt. OR clinical trial.pt OR exp Clinical Trials as topic/) OR ((clinical adj trial\$).tw. OR ((singl\$ or doubl\$ or treb\$ or tripl\$) adj (blind\$3 or mask\$3)).tw. OR PLACEBOS/ OR placebo\$.tw. OR randomly allocated.tw. OR (allocated adj2 random\$).tw.)) NOT (case report.tw. OR letter/ OR historical article/)) AND ("Sambucus niger" OR "Sambucus nigra" OR Sambuc\* OR Elderberry.af.) AND ((Influenza, Human/ OR Influenza A Virus, H1N1 Subtype/ OR Influenza A virus/ OR Influenza A Virus, H3N2 Subtype/ OR H1N1.mp.) OR (MERS−COV.mp. OR Middle East Respiratory Syndrome Coronavirus OR SARS OR severe acute respiratory syndrome/) OR ((breathing or lung or pulmonary or respir\$).af.))

2.5. Screening and data extraction {#sec0045}
----------------------------------

One author (KO) scanned the title and abstract of each record retrieved. All articles that appeared to meet the selection criteria were accessed and evaluated in full text. For articles that met the inclusion criteria, two authors (KO and JMC) extracted the relevant population and intervention characteristics into an extraction template, with any disagreements resolved by discussion with AS. Where duplicate papers and papers reporting aspects of the primary study, the authors (JMC and AS) checked the data aligned before removing the secondary paper and the original publication (typically the older paper) was included.

The risk of bias of each study was evaluated by KO and JMC, using the Cochrane Collaboration Risk of Bias tool \[[@bib0030]\], and checked by AS. Any disagreements were resolved by consensus. The Cochrane Risk of Bias tool is comprised of seven domains including; random sequence generation; allocation concealment; blinding of participants and personnel; blinding of outcome assessors; incomplete outcome data; selective outcome reporting; and other sources of bias. Reviewers designated a judgement related to the risk of bias for each item. \'Yes\' indicated a low risk of bias, and \'No\' a high risk of bias and \'Unclear\' indicating unclear or unknown risk of bias.

2.6. Data analysis {#sec0050}
------------------

Data were synthesised in narrative form. Due to the heterogeneity of the data, a meta-analysis was not conducted.

3. Rapid review results {#sec0055}
=======================

The database search identified 40 studies. After the removal of duplicates (n = 10), 30 studies were screened by title and abstract. This resulted in the exclusion of 15 studies. The remaining 15 studies were screened as full text. Ten studies were excluded as they reported the wrong study design (n = 4), were a systematic review (n = 4) or duplicated already included studies (n = 2). Five studies were included for full review. (see [Table 1](#tbl0005){ref-type="table"} )Table 1Summary of Included Studies.Table 1IdentificationMethodsInterventionOutcomesAuthor (date)CountryDesignStudy durationStatistical method (s)Study Population (age)Disease or ConditionIntervention (single or mixed formula)Administration*Dose*Duration of TreatmentControl or PlaceboMeasure of OutcomeOutcomeZakay-Rones, Z et al (1995)Israel*In-vitro* plus double-blind clinical trial -3 days plus 6 days follow-upFisher exact test; odds ratio summary measuren = 27;\
5--56 years;Influenza A; Influenza B; RSV; adeno-RSV; clinical trial during Influenza B/PanamaSingle formula - Sambucol - standardized extract of Sambucus nigra berriesoral (syrup)children = 2 tablespoons daily; adults = 4 tablespoons daily3 daysplaceboSymptom reduction - fever improvementTreatment: mean = 2.36 ± 0.9 day\
Control: 3.33 ± 1.5 daysSymptom improvement - day 1Treatment: 20%,\
Control: 8.3%Symptom improvement - day 2Treatment: 73.3%\
Control: 16.7%Symptom improvement - day 3Treatment: 6.7%\
Control =  33.3%Duration of illness (no. of days)Treatment: 2.7 days\
Control: 4 daysZakay-Rones, Z et al (2004)Israel, Norway, SwedenRandomized, double-blind, placebo-controlled; multi-centre (n = 4)5 days plus 5 days follow-upContinuous variables - mean values student\'s t; two-tailed tests; analysis of variance with repeated measures; analysisn = 60;\
18--54 yearsinfluenza-like symptomsStandardised extract of Sambucus nigra berries (Sambucol) - 38% in a syrup also containing raspberry extract, glucose, citric acid and honey.oral (syrup)15 ml - 4 per day5 daysPlacebo (Conventional concomitant medications permitted including analgesic and/or metered dosage nasal spray)Symptom observation via visual analogue scale - at baseline, 4 times per day + twice daily for five days post treatment.*Symptom reduction --* Treatment: 3--4 days\
Control: 7--8 days\
Full recovery by all by day 8;Measures = no improvement - pronounced; improvement on 10 point scale;*Pronounced improvement --* Treatment: mean 3.1 days (SD 3.1)\
Control: 7.1 days (SD 2.5) (p\<0.001)Use of \'rescue\' medicationLess use of \'rescue\' medication by treatment group (p\<0.001)Tiralongo, E et al (2016)AustraliaRandomized, double-blind placebo-controlled clinical trialApril 2013 - December 2014Chi Square or Fischer\'s exact test; ANOVA group comparisonN = 312\
Mean: 51y (SD 16)Common coldStandardised extract, membrane filtered, 300 mg of elderberry extract (22% polyphenols 15% anthocyanins and 150 mg of rice flour. The 300 mg elderberry extract also contain several mineral, trace elements and vitamins including relatively high levels of magnesium 1.19 mg (3.97 mg/g).oral (capsules)Priming dose = 2 capsules per day; Overseas dose = 3 capsules per dayBetween 15 and 16 days - variable by travel duration per participantplaceboCold episodes (total number of days measured for previous 6 days)No difference between groupsCold duration (no. days)Treatment: 57 days\
Control: 117 days\
(p = 0.05)Cold symptoms (score)\
Treatment: 247 Control: 583 (p = 0.02)Co-medication (eg nasal spray, cold tablets, analgesic, antibiotic)No difference between groups.Kong, F (2009)ChinaPilot, randomized, double‐blind, placebo‐controlled clinical trial2 daysTwo‐tailed testsN = 64\
16--60 yearsinfluenza175 mg of the proprietary elderberry extract plus non‐active ingredients (maltodextrin, dextrose, fructose, silica, citric acid, natural flavors, cyclodextrin and magnesium stearate).Slow‐dissolve lozenge175mg - 4 per day2 daysplaceboTotal symptom severity -- 48 hours (VAS score)Treatment: no symptoms (n=9; 28%), some symptom relief (one or two mild symptoms; VAS=1) (n=19; 60%), mean VAS score 0.28 (SD 0.63).\
Control: No participants had symptom resolution or relief.Fever -- 48 hours (VAS score)Treatment: Decreased from baseline (2.67, SD 1.80) to 0.47 ± 0.64 (p\<0.0001).Headaches -- 48 hours (VAS score)Treatment: Decreased from baseline 4.47 (SD 2.14) to 1.53 (SD 1.41) (p\<0.0001) Control: increased from 3.78 (SD 1.66) to 5.25 (SD 1.34) (p\<0.0001)Muscle aches -- 24 hours, 48 hours (VAS score)*24 hours*\
Treatment: Decreased from baseline (2.87, SD 2.13) to 1.19 (SD 1.05) (p=0.0002)\
*48 hours*\
Treatment: 0.16 (SD 0.45) by 48 hours.\
Control: Increased from baseline 2.13 (SD 2.10) to 3.47 (SD 1.50) (p=0.0013)Nasal congestion -- 24 hours, 48 hours (VAS score)*24 hours*\
Treatment: Decreased from baseline 4.03 (SD 2.10) to 1.47 (SD 1.14 (p\<0.0001)\
*48 hours*\
Treatment:\
0.56 (SD 0.62)\
Control: increased from baseline 3.30 (SD 1.71) to 4.26 (SD 1.81) (p=0.049).Nasal mucus discharge - 48 hours (VAS score)Treatment: Decreased from baseline 1.94 (SD 1.61) to 0.50 ± 0.52 (p = 0.0019) Control: No significant improvement.Coughing - 48 hours (VAS score)Treatment: No significant change from baseline Control: increased from baseline 2.19 (SD 1.47) to 3.69 (SD 1.25) (p = 0.0041).Raus et al. (2015)Czech RepublicDBRCT double dummy, multicentre10 daysWilcoxon testN = 473\
12--70 years (\<18 years, n = 9)Active influenza symptomsHydroethanolic extract (65% v/v) of freshly harvested *Echinacea purpurea*. extraction ratio 1:12 of herb and 1:11 from the roots combined at a ratio of 95% to 5%. 240mg of the active ingredient concentrated to extractum spissum, supplemented with 276.5 mg Sambucus fructus succus recentis and excipients to give 1 mL Echinaforce HotdrinkExperimental group: 5 mL Echinaforce Hotdrink in 150 mL hot water and 3 × 5 mL in 150 mL hot water and placebo oseltamivir Placebo group: Echinaforce hot drink placebo (same dose as above) and Oseltamivir verum Oseltamivir placebo5 times/day BD BD 5 times/day BD BD BDDays 1--3 Days 4--10 Days 1--10 Days 1--3 Days 4--10 Days 1--5 Days 6--10Echinaforce Hotdrink placebo contained the same excipients as the verum plus colorants and flavors. Oseltamivir placebo was manufactured by overen. Capsulation of original oseltamivir capsules using opitically dense dark green gelatin capsules filled with microcrystalline celluloseCumulative proportion of patient with influenza symptoms alleviated (Day 1)Treatment: 1.5% Control: 4.1%Cumulative proportion of patient with influenza symptoms alleviated (Day 5)Treatment: 50.2%\
Control: 48.8%Cumulative proportion of patient with influenza symptoms alleviated (Day 10)Treatment: 90.1%\
Control: 84.8%Non-inferiority of treatment vs control (generalized Wilcoxon test)P\[x\<Y\] = 0.5068; 95% CI, 0.4871--0.5265.\
No difference found in subgroup of virologically confirmed influenza, and\
in retrospective analysis during the peak influenza period.Incidence of recovery (the first day when cough, nasal obstruction, sore throat, fatigue, headache, myalgia, and feverishness were rated as absent or mild in the evening).Recovery rates were similar between the two groups.Adverse eventsTreatment: 2.46%\
Control: 6.45%; (P =  0.076)

Included studies were conducted in China \[n = 1\], Australia \[n = 1\], Israel \[n = 1\], Czech Republic \[n = 1\] and Norway \[n = 1\]. All studies were randomized, double-blind controlled trials. Four studies used a placebo control, and one study \[[@bib0035]\] used an active control (i.e. oseltamivir). The duration of included studies ranged from 2 to 16 days.

The included studies involved a total of 936 participants (minimum 27, maximum 473, mean 187). The study population were primarily adults aged between 18 and 70 years, with two studies also including children aged from 5 years \[[@bib0035]\] or 12 years \[[@bib0040]\]. The most common conditions studied were influenza \[[@bib0035], [@bib0040], [@bib0045]\] and influenza-like symptoms \[[@bib0050]\], followed by common cold \[[@bib0055]\].

All included studies used a proprietary herbal medicine product as the intervention. Four studies used mono-herbal preparations of *S.nigra* berry extract \[[@bib0035],[@bib0045], [@bib0050], [@bib0055]\]. One study used a poly-herbal preparation, which contained *S.nigra* berry plus *Echinacea purpurea* root \[[@bib0040]\]. The preparations were administered orally in the form of a syrup \[[@bib0035],[@bib0050]\], capsules \[[@bib0055]\], granules \[[@bib0040]\] or lozenges \[[@bib0045]\]. Doses ranged from 15 mLs four times per day (syrup), 3 capsules per day, 175 mg lozenge four times per day or 5 mL of the poly-herbal formula in 150 mL of hot water using an initial dosage of 5 times per day for days 1−3 followed by a maintenance dose of twice per day (days 4−10).

3.1. Critical appraisal {#sec0060}
-----------------------

As presented in [Table 2](#tbl0010){ref-type="table"} , the risk of bias assessment for the first domain (randomisation process) resulted in all 5 studies being rated as having a low risk of bias \[[@bib0035], [@bib0040], [@bib0045], [@bib0050], [@bib0055]\]. For domain 2 (treatment assignment), two studies were considered to have some concerns \[[@bib0040],[@bib0045]\], and three studies were rated as having low risk of bias \[[@bib0035],[@bib0050],[@bib0055]\]. Under domain 3 (missing outcome data), all five trials were judged as having low risk of bias \[[@bib0035], [@bib0040], [@bib0045], [@bib0050], [@bib0055]\]. For domain 4 (measure of outcomes), all five studies were rated as having low risk of bias \[[@bib0035], [@bib0040], [@bib0045], [@bib0050], [@bib0055]\]. In domain 5 (selective reporting), all trials were judged to be at low risk of bias \[[@bib0035], [@bib0040], [@bib0045], [@bib0050], [@bib0055]\]. Overall, two studies were identified as having some concerns \[[@bib0040],[@bib0045]\] and three studies were judged as having low risk of bias \[[@bib0035],[@bib0050],[@bib0055]\]. These judgements should be taken into consideration when interpreting the findings of this review.Table 2Critical appraisal of Included Studies.Table 2Author (date)Randomisation processTreatment assignmentMissing outcome dataMeasure of outcomesSelective reportingOverall risk of biasZakay-Rones, Z et al. (1995)LowLowLowLowLowLowZakay-Rones, Z. et al (2004)LowLowLowLowLowLowTiralongo, E. et al (2016)LowLowLowLowLowLowKong, F (2009)LowLowSome concernsLowLowSome concernsRaus, K. et al. (2015LowLowSome concernsLowLowSome concerns

3.2. Summary of findings {#sec0065}
------------------------

Treatment outcomes reported included overall reduction in symptoms; duration of illness/rate of recovery, and the use of rescue medication including analgesics, nasal spray, cold tablets, antibiotics.

Four studies \[[@bib0035],[@bib0045], [@bib0050], [@bib0055]\] measured reduction of symptoms; fever reduction \[[@bib0035],[@bib0045], [@bib0050], [@bib0055]\] and one study \[[@bib0045]\] also reported reduction of headache, muscle ache, nasal congestion and mucus discharge and cough All studies reported \[[@bib0035],[@bib0050],[@bib0055]\] a reduction in overall symptom severity among participants receiving *S.nigra* berry (whether in mono- or poly-herbal formulation) when compared with controls. One study reported that participants receiving treatment reported significant improvement in symptom severity following 48 h whereas the control group reported increased severity in the same time-period \[[@bib0040]\]. Duration of illness and rate of recovery was reported in four studies \[[@bib0035],[@bib0040],[@bib0050],[@bib0055]\]. Three studies demonstrated that the duration of illness was almost 50 % shorter for those receiving *S.nigra* berry compared with the control group \[[@bib0035],[@bib0050],[@bib0055]\]. In one study, the rate of recovery was similar between a *S.nigra* polyherbal preparation and an active control (Oseltamivir) \[[@bib0040]\].

In the two studies \[[@bib0050],[@bib0055]\] reporting the use of rescue medication including analgesics, antibiotics, nasal sprays, or cold tablets to manage participant symptoms, the need for such medication was found to be inconsistent. In one study, participants assigned to *S.nigra* berry treatment reported using rescue medication to manage influenza-like symptoms less frequently than control participants \[[@bib0050]\]. By contrast, a second study found no difference between groups in the reported use of rescue medication or prescribed antibiotics among participants with the common cold \[[@bib0055]\].

3.3. Adverse events {#sec0070}
-------------------

Adverse events were rare with one study \[[@bib0055]\] reporting two adverse events (fatigue and cold-like symptoms) attributed to *S.nigra* berry compared to three (itchy throat, fatigue and kidney pain) attributed to placebo. A second study \[[@bib0040]\] reported nine adverse events (nausea and vomiting) attributed to treatment (a poly-herbal formulation containing *S.nigra* berry and *Echinacea purpurea* extract) compared with 18 reported adverse effects attributed to the comparator (Oseltamivir). No serious adverse events were reported.

3.4. Clinical significance {#sec0075}
--------------------------

Overall, the evidence obtained from the five studies included in this review involving 936 people suggests that mono-herbal preparations of *S.nigra* berry when taken close to the onset of symptoms and for up to two weeks, may assist in relieving the symptoms of the common cold and influenza. *S.nigra* berry may be effective in reducing the duration and severity of fever, headache, nasal congestion and nasal mucous discharge when associated with an acute viral respiratory infection. Some evidence suggests that *S.nigra* berry may relieve cough or help prevent the worsening of cough when attributed to such viral infections however this finding is inconsistent across studies. As the formulation, dose and duration of *S.nigra* berry treatment varied between studies, general recommendations regarding these clinically important factors cannot be made. Accordingly, TGA-approved monographs and pharmacopoeias \[[@bib0060]\] and the studies included in this review should be consulted when making decisions regarding dosing of *S.nigra* berry treatment. It is important to note that none of the studies included evaluation of the use of *S.nigra* berry in pregnant and/or breastfeeding women or in people with chronic or complex conditions. No studies investigated the use of *S. nigra* berry in the treatment, prevention, or relief of symptoms of COVID-19. While there is some evidence to suggest *S.nigra* berry increases inflammatory cytokines IL-1 beta, TNF-alpha, IL-6, IL-8 \[[@bib0065]\], there is no strong evidence to date to support that *S.nigra* berry can contribute to a cytokine storm. Both efficacy and safety studies are warranted to answer these important clinical questions.

Disclaimer {#sec0080}
==========

This article should not replace individual clinical judgement. The views expressed in this rapid review are the views of the authors and not necessarily from the host institutions. The views are not a substitute for professional medical advice.
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